NOG-FcgR KO mouse (Next Generation Severely Immunodeficient NOG mouse)
Strain name: NOG-FcgR KO (FcResolv NOG / NOG-F) mouse
NOG-FcgR KO (NOG-F) mouse 개요
NOD.Cg-Fcer1g<tm1Rav>Fcgr2b<tm1Ttk> 마우스와 NOG 마우스의 교배.
Scid mutation and the IL-2Rγc target allele 확립.
This strain is deleted FcgR gene of NOG mouse.
NOG 마우스를 기본으로 마우스 대식세포(Macrophage)의 표면에 존재하는 Fc receptor의 gamma chain을 결손.
마우스 선천적 면역의 약화. (Attenuation of mouse innate immunity)
Antitumor effect by Nivolumab & Keytruda.
6주령만 공급이 가능한 동물입니다.
Growth of HSC4, NCI-H1975, and HCC827 cancer cell lines were strongly suppressed or rejected by treatment with Nivolumab in humanized FcResolv NOG mouse, but neither was suppressed in conventional humanized NOG mouse.
(Katano et al. Scientific reports 2021)
NOG-FcgR KO (NOG-F) mouse 특징
인간 조혈줄기세포가 이식된 Hu. FcResolv NOG 마우스에서 면역관문억제항체의 항종양 효과를 명확하게 평가.
면역관문억제제의 항종양 평가 모델 (Model for an antitumor evaluation of immune checkpoint inhibitors)
Pathological analysis by immunohistochemistry (IHC):
HSC4, NCI-H1975, and HCC827 cancer cell lines transplanted into humanized FcResolv NOG mouse treated with Nivolumab showed enhanced infiltration of human CD4+ and CD8+ T cells, whereas the RKO cancer cell line did not increase.
In conventional humanized NOG mouse, only a small number of human T-cell infiltrates were observed after nivolumab administration.
새론바이오는 일본 CIEM의 NOG-FcgR KO (NOG-F) 마우스를 공급합니다.
